Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Teva
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com
Investors sue Teva over $41B Actavis deal - Drug Delivery Business
Teva, chasing Amgen's Aimovig, scores much-needed FDA approval for migraine drug Ajovy | Fierce Pharma
Teva puts the brakes on troubled California sterile injectables plant: reports | Fierce Pharma
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
FDA's Call on Migraine Drug Could Be Trouble for Teva | Barron's
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva: Definitely Undervalued (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals (@TevaUSA) / Twitter
Sosei see Teva pipeline cull as an opportunity | pharmaphorum
A Look at Teva's Generic Drugs Research Pipeline
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
Teva refiles long-acting schizophrenia drug after FDA rejection
Teva and Nuvelution partner on Tourette drug development
FDA accepts Teva-MedinCell's new drug application for schizophrenia drug
Teva Develops First FDA-Approved Digitally-Integrated Inhaler
Generic NSCLC treatment launched by Teva
EX-99.1
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
FDA warns of ADHD drug shortage on Teva manufacturing delays - www.israelhayom.com
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
TEVA | Market Realist
Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire
Plant issues plague Celltrion and Teva as FDA issues two biosimilars CRLs
Teva Pharmaceutical Industries Ltd (TEVA) - Product Pipeline Analysis, 2021 Update
